Posted by Michael Wonder on 06 Apr 2023
Enanta Pharmaceuticals receives FDA fast track designation for EDP-323, its oral, L-protein inhibitor in development for the treatment of respiratory syncytial virus
6 April 2023 - Enanta Pharmaceuticals today announced that the US FDA has granted fast track designation for EDP-323, Enanta’s L-protein inhibitor in development for the treatment of respiratory syncytial virus.
EDP-323 is being evaluated in a Phase 1 double-blind, placebo-controlled study designed to assess its safety, tolerability, and pharmacokinetics.
